Caspase 9
Caspase 9 plays a central role in the mitochondrial, or intrinsic, apoptotic pathway, where cytochrome c release promotes apoptosome formation with Apaf-1 and procaspase-9[1]. Mechanistically, activated caspase 9 cleaves and activates effector caspases 3 and 7, linking mitochondrial dysfunction to proteolytic cell death execution[1][2]. In disease models, diminished Apaf-1 activity reduced cytochrome c-dependent caspase activation in ovarian cancer cell lines, while ischemic hippocampal neurons showed caspase 9 activation before neuronal death[2][3]. Compared with caspase 8 in the extrinsic pathway, caspase 9 primarily mediates the intrinsic route to caspase 3 activation in ischemic neurons and TNFR-mediated hepatocyte apoptosis[3][4]. For experimental applications, Apaf-1 ligands inhibited apoptosome-mediated procaspase-9 activation and reduced apoptotic phenotypes in mitochondrial apoptosis models[5].
References:
- [1]. Allan LA, et al. Apoptosis and autophagy: Regulation of caspase-9 by phosphorylation. FEBS J. 2009 Nov;276(21):6063-73. [Content Brief]
- [2]. Wolf BB, et al. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem. 2001 Sep 7;276(36):34244-51. [Content Brief]
- [3]. Cao G, et al. Cloning and characterization of rat caspase-9: implications for a role in mediating caspase-3 activation and hippocampal cell death after transient cerebral ischemia. J Cereb Blood Flow Metab. 2002 May;22(5):534-46. [Content Brief]
- [4]. Imao M, et al. Differential caspase-9-dependent signaling pathway between tumor necrosis factor receptor- and Fas-mediated hepatocyte apoptosis in mice. Liver Int. 2006 Feb;26(1):137-46. [Content Brief]
- [5]. Malet G, et al. Small molecule inhibitors of Apaf-1-related caspase- 3/-9 activation that control mitochondrial-dependent apoptosis. Cell Death Differ. 2006 Sep;13(9):1523-32. [Content Brief]
-
Caspase 9 Related Products (197)
Related Products (197)
-
Antibodies (2)
-
Astin B
0 ImagesCat. No.: HY-P3148CAS No.: 151201-76-2Astin B is a orally active and potent cyclic pentapeptide, that can be isolated from Aster tataricus. Astin B has hepatotoxic effects in vitro and in vivo and that hepatic injury was primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B induces autophagy in L-02 cells, increases LC3-II and decreases p62 expression.
-
Anticancer agent-364
0 ImagesCat. No.: HY-189286Anticancer agent-364 is a phenylalanine-derived hydrazone heterocyclic compound that exhibits selective cytotoxicity against NSCLC lung cancer cells. Anticancer agent-364 inhibits VEGF-A, VEGFR-1, and VEGFR-2, increases caspase-3/7, caspase-8, and caspase-9 activity, and induces apoptosis. Anticancer agent-364 can be used for research on non-small cell lung cancer.
-
EGFR-IN-109
0 ImagesCat. No.: HY-162360CAS No.: 3019971-97-9
-
HDAC-IN-91
0 ImagesCat. No.: HY-175021HDAC-IN-91 is a multiple inhibitor of HDAC (IC50 = 134.22 nM for HDAC1, 66.29 nM for HDAC2), carbonic anhydrase (CA) (Ki = 72.03 nM for CA IX, 50.76 nM for XII), and tubulin polymerization ( IC50 = 2.56 μM). HDAC-IN-91 inhibits PARP1 and increases the Bax/Bcl-2 ratio. HDAC-IN-91 blocks the cell cycle at the G2/M phase and induces apoptosis through a mitochondrial apoptosis activation mechanism. HDAC-IN-91 can exert potent cytotoxic activity through tubulin polymerization inhibition. HDAC-IN-91 can be used in breast, colorectal, cervical and lung cancer research.
-
BTX306
0 ImagesCat. No.: HY-177740CAS No.: 2230747-62-1BTX306 is a cereblon-targeting molecular glue degrader. BTX306 reduces myeloma cell viability and induces apoptosis. BTX306 overcomes myeloma cell resistance to Lenalidomide (HY-A0003) or Bortezomib (HY-10227). BTX306 is active against primary myeloma cells, and shows efficacy in vivo. BTX306 can be used for myeloma research.
-
PDGFRA/CAIX/XII-IN-1
0 ImagesCat. No.: HY-181587Purity: 98.10%PDGFRA/CAIX/XII-IN-1 is an inhibitor of PDGFRA, CA IX and CA XII, with an IC50 of 20 nM against PDGFRA, a Ki of 93.3 nM against CA IX, and a Ki of 80.0 nM against CA XII. PDGFRA/CAIX/XII-IN-1 binds to the ATP-binding pocket of PDGFRA and blocks the downstream STAT3, AKT and ERK1/2 signaling pathways. PDGFRA/CAIX/XII-IN-1 induces G0/G1 cell cycle arrest and endogenous apoptosis (Apoptosis), including cleavage of PARP-1, caspase-9 and caspase-3, activation of caspase 3/7, and down-regulation of Mcl-1. PDGFRA/CAIX/XII-IN-1 exhibits antiproliferative activity in eosinophilic leukemia cells. PDGFRA/CAIX/XII-IN-1 can be used for the research of leukemia.
-
EGFR/BRAFV600E-IN-6
0 ImagesCat. No.: HY-180154CAS No.: 3120155-78-1EGFR/BRAFV600E-IN-6 (Compound 7c) is a dual EGFR/BRAFV600E inhibitor with IC50 values of 0.12 and 0.05 μM. EGFR/BRAFV600E-IN-6 can activate caspase-3/8/9, unregulate Bax expression and downregulate Bcl-2 levels. EGFR/BRAFV600E-IN-6 can induce apoptosis and shows antioxidant activity. EGFR/BRAFV600E-IN-6 can be used for the research of cancer, such as colon cancer.
-
CHNQD-01522
0 ImagesCat. No.: HY-181675CHNQD-01522 is a microtubule inhibitor targeting the colchicine binding site on β-tubulin. CHNQD-01522 binds to the colchicine binding site on β-tubulin, inhibits microtubule polymerization, and evades P-glycoprotein transport in cancer cells. CHNQD-01522 inhibits proliferation, suppresses tumor cell colony formation, arrests cell cycle in G2/M phases, and induces apoptosis in cancer cells. CHNQD-01522 upregulates of Bax and activation of caspase-9 and caspase-3. CHNQD-01522 shows anti-tumor efficacy in subcutaneous and orthotopic hepatocellular carcinoma xenograft tumor models. CHNQD-01522 can be used for the research of hepatocellular carcinoma.
-
EGFR-IN-201
0 ImagesCat. No.: HY-181659CAS No.: 3103654-99-2EGFR-IN-201 is a potent EGFR inhibitor, with an IC50 of 0.091 μM against wild-type EGFR; for mutant EGFR variants, the IC50 values of EGFRT790M, EGFRL858R and EGFRC797S are 0.147 μM, 0.221 μM and 0.703 μM, respectively. EGFR-IN-201 inhibits EGFR downstream signaling proteins AKT1 (IC50 = 0.225 μg/mL) and ERK1 (IC50 = 0.705 μg/mL). EGFR-IN-201 induces G0/G1 cell cycle arrest, apoptosis and low-level necrosis in cancer cells. EGFR-IN-201 is applicable to research on cancers such as colon cancer.
-
HDAC6-IN-63
0 ImagesCat. No.: HY-178022HDAC6-IN-63 (Compound 7) is an orally active HDAC6 inhibitor with an IC50 of 145 nM. HDAC6-IN-63 inhibits the expression of Sp1 and RAD51, thereby inducing Caspase-dependent apoptosis. HDAC6-IN-63 has antitumor activity and sensitizes Etoposide (HY-13629) and Gemcitabine (HY-17026), promoting synergistic death of NSCLC cells through the inhibition of homologous recombination and non-homologous end joining (NHEJ) pathways involved in DNA DSB repair. HDAC6-IN-63 can be used for chemotherapy of cancers like NSCLC research.
-
EGFR-IN-134
0 ImagesCat. No.: HY-168623EGFR-IN-134 (compound 3f), a triazolo[3,4-a]isoquinoline derivative, is a potent EGFR inhibitor with an IC50 of 0.023 µM. EGFR-IN-134 induces apoptosis and necrosis. EGFR-IN-134 initiates cell cycle arrest at the G2/M and pre-G1 phases, downregulates anti-apoptotic protein Bcl2 and upregulates pro-apoptotic proteins: p53, Bax, and caspases 3, 8, and 9. EGFR-IN-134 shows antiproliferative and anticancer activity.
-
13'-Carboxy-δ-tocopherol
0 ImagesCat. No.: HY-N17653CAS No.: 1160974-35-513'-Carboxy-δ-tocopherol is a metabolite of long-chain vitamin E.13'-Carboxy-δ-tocopherol exhibits antiproliferative properties in cancer cells. 13'-Carboxy-δ-tocopherol activates caspase-3, caspase-9, causes PARP-1 cleavage, reduces mitochondrial membrane potential, increases ROS formation, and drives apoptosis.13'-Carboxy-δ-tocopherol can be used for the research of hepatocellular carcinoma.
-
Ginsenoside Rh2 (Standard)
0 ImagesSynonyms: 20(S)-Ginsenoside Rh2(Standard); 20(S)-Rh2(Standard)
-
EM20-25
0 ImagesCat. No.: HY-101999CAS No.: 141266-44-6EM20-25 is an inhibitor for Bcl-2, which interferes with the interaction between BCL-2 and BAX, activates caspase-9 and thus induces the apoptosis. EM20-25 affects the mitochondrial function, causes the open of permeability transition pore (PTP). EM20-25 enhances the sensitivity of cells to Staurosporine (HY-15141), and enhances the killing effect of BCL-2-expressing leukemia cells to Chlorambucil (HY-13593) and Fludarabine (HY-B0069).
-
CDC25A/NF-κB-IN-1
0 ImagesCat. No.: HY-184446CDC25A/NF-κB-IN-1 is an effective dual-target inhibitor of CDC25A and NF-κB, and is a prodrug of Pt(IV). CDC25A/NF-κB-IN-1 has anticancer activity and low cytotoxicity to normal cells. CDC25A/NF-κB-IN-1 can trigger a variety of anticancer mechanisms, including S phase cell cycle arrest, mitochondrial endogenous apoptosis, endoplasmic reticulum stress, autophagy-dependent ferroptosis. CDC25A/NF-κB-IN-1 has good safety and can be used for ovarian cancer research.
-
NSC 850745
0 ImagesCat. No.: HY-175848NSC 850745 is a selective and potent c-Met/STAT3 inhibitor with IC50 values of 210 and 670 nM. NSC 850745 can inhibit cell proliferation, induce G2/M phase arrest and induce apoptosis. NSC 850745 can downregulate AKT-1, VEGF and Bcl-2 expression and upregulate p53, Bax and caspase expression. NSC 850745 can be used for the research of cancer, such as leukemia and colon cancer.
-
MAPK-IN-5
0 ImagesCat. No.: HY-175175CAS No.: 2579683-39-7MAPK-IN-5 is a potent MAPK inhibitor with an IC50 of 1.35 μM against HeLa cells. MAPK-IN-5 inhibits HeLa cell proliferation by inducing ROS-mediated DNA damage and mitochondrial apoptosis via the MAPK pathway. MAPK-IN-5 significantly inhibits colony formation, reduces the number of live cells, suppresses cell migration, and causes cell cycle arrest in the G2/M phase in HeLa cells. MAPK-IN-5 can be used for the study of cervical cancer.
-
DZ-1-DHA
0 ImagesCat. No.: HY-184557CAS No.: 2223036-84-6DZ-1-DHA is a conjugate of DHA (HY-B2167) and DZ-1 dye. DZ-1-DHA mediates selective cellular uptake via binding to overexpressed OATP1A2. DZ-1-DHA induces the cleavage of Caspase-3, Caspase-8, Caspase-9 and PARP-1. DZ-1-DHA induces Apoptosis and Ferroptosis. DZ-1-DHA induces ROS production through a Fenton-like mechanism, causes mitochondrial membrane depolarization, and triggers lipid peroxidation. DZ-1-DHA can be used in studies related to colorectal cancer liver metastasis.
-
Bax activator-2
0 ImagesCat. No.: HY-182349CAS No.: 3034297-25-8Bax activator-2 is a pro-apoptotic agent targeting BAX, with an IC50 of 0.30 μM against human BAX. Bax activator-2 binds to the trigger site of BAX and induces its conformational change. Bax activator-2 induces mitochondrial depolarization, cytochrome c release, cleavage of caspase-3/9 and PARP, thereby initiating apoptosis. Bax activator-2 exhibits cytotoxicity against a variety of cancer cell lines. Bax activator-2 can be used in research related to acute myeloid leukemia and solid tumors.
-
XIAP-CASP7 PPI-IN-1
0 ImagesCat. No.: HY-175177Xiap-casp7 PPI-IN-1 is a reversible XIAP: CASP7 inhibitor with specifically disrupting the interaction between XIAP and CASP7. XIAP-CASP7 PPI-IN-1 selectively induce MCF-7 and other caspase-3 down-regulation (CASP3/DR) triple-negative breast cancer cell apoptosis. XIAP-CASP7 PPI-IN-1 overcomes chemoresistance via down-regulating β-catenin and its associated ABC transporters in Paclitaxel (HY-B0015)-resistant MCF-7 cells. XIAP-CASP7 PPI-IN-1 can be used for the study of breast cancer.
